Don’t miss this list of resources for University of Illinois Cancer Center trainees, everything from funding opportunities and conferences to training, webinars and workshops. Email the Cancer Center’s Cancer Research Training and Education Coordination (CRTEC) team at [email protected] for more information or assistance.
Funding Opportunities
- 2025 Harold M. Weintraub Graduate Student Award
- NEI Expand OHDSI Initiative for Eye Care and Ocular Imaging Challenge
- Data Science careers at NIH
- CCTS Pilot Grant Program
- Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (U24 Clinical Trials Not Allowed)
- Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required)
- Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) – Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
- Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
- NOITP: The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)
- NOITP: The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
- Career Development Opportunities for Research on Cancer in Global Settings at the Center for Global Health at the National Cancer Institute
- Administrative Supplements to Promote Diversity in Research and Development Small Businesses SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
- Notice of Special Interest (NOSI): Administrative Supplements for Assessing Capacity to Address Obesity for Cancer Prevention and Control
- Mechanisms that impact Cancer Risk after Bariatric Surgery: PAR-25-043 (R01 Clinical Trial Optional) and PAR-25-044 (R21 Clinical Trial Not Allowed)
- Microbial-based Cancer Imaging and Therapy – Bugs as Drugs funding opportunities: R01 Clinical Trial Not Allowed (PAR-25-107) and R21 Clinical Trial Not Allowed (PAR-25-108)
- Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) (PA-25-172)
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) (PA-25-253) - Co-infection and Cancer funding opportunities: R01 Clinical Trial Not Allowed (PAR-25-082) and R21 Clinical Trial Not Allowed (PAR-25-083)
- Cancer Prevention and Control Clinical Trials Planning Grant Program funding opportunities: U34 Clinical Trials Optional (PAR-25-103) and R34 Clinical Trials Optional (PAR-25-104)
- Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) (PAR-25-145)
- Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) (PAR-25-221)
- Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) (PAR-25-221)
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) (PAR-24-311)
- Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) (PAR-25-106)
- Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) (PAR-25-175)
- Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
- Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
- Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
- Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
- Co-infection and Cancer (R01 Clinical Trial Not Allowed)
- Co-infection and Cancer (R21 Clinical Trial Not Allowed)
- Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
- Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
- Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
- Microbial-based Cancer Imaging and Therapy – Bugs as Drugs (R01 Clinical Trial Not Allowed)
- Microbial-based Cancer Imaging and Therapy – Bugs as Drugs (R21 Clinical Trial Not Allowed)
- NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
- Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
- Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
- Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
- Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
- Integrating Mental Health Care into Health Care Systems and Non-Health Settings in Low- and Middle-Income Countries (R01 Clinical Trial Optional)
- Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
- Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) (PAR-25-134)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) (PAR-25-272)
- The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) (PAR-25-292)
- Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) (PAR-25-275)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics funding opportunities: R01 Clinical Trial Optional (PAR-25-069) and R21 Clinical Trial Not Allowed (PAR-25-070)
- Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) (PAR-25-094)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes funding opportunities: R01 Clinical Trial Not Allowed (PAR-25-095) and R21 Clinical Trials Not Allowed (PAR-25-096)
- NCMRR Early Career Research Award (R03 Clinical Trial Optional) (PAR-25-124)
- Biology of Bladder Cancer funding opportunities: R21 Clinical Trial Optional (PAR-25-128) and R01 Clinical Trial Optional (PAR-25-129)
- Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) (PAR-25-152)
- Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) (PAR-25-171)
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) (PAR-25-248)
- Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) (PAR-25-254)
- Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) (PAR-25-072)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed) (PA-25-173)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) (PA-25-174)
- Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) (PA-25-294)
- Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) (PA-25-295)
- NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) (PAR-24-316)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) (PAR-25-069)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) (PAR-25-070)
- Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) (PAR-25-072)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) (PAR-25-069)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) (PAR-25-070)
- Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) (PAR-25-072)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) (PAR-25-096)
- Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) (PAR-25-109)
- Biology of Bladder Cancer (R21 Clinical Trial Optional) (PAR-25-128)
- Biology of Bladder Cancer (R01 Clinical Trial Optional) (PAR-25-129)
- NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) (PAR-25-135)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) (PAR-25-148)
- Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) (PAR-25-152)
- Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) (PAR-25-152)
- Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) (PAR-25-152)
- Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) (PAR-25-275)
- Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required) (PAR-26-001)
- Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
- Advancing Genomic Medicine Research (R21 Clinical Trial Optional) (RFA-HG-25-003)
Conferences, Seminars, Webinars and Workshops
- NCI Workshop – In Vivo Engineering of Immune Cells for Cancer Immunotherapy: January 28-29
- University of California, Davis Comprehensive Online Course in Flow Cytometry: February 3-7
- Cold Spring Harbor Laboratory Innovators Symposium: February 24-26
- 2025 Sexual & Gender Minority Cancer CARE Workshop: February 26 – March 1
- NCI Symposium on Translational Technologies for Global Health: March 19-20
- 2025 NCI RNA Biology Symposium: April 3-4
- Chicago K Day 2025: February 6
- AACR Annual Meeting 2025: Submit an Abstract: April 25-30
- NCI Workshop: Transformative Microsystem Technologies for Cancer Diagnostics, Management, and Treatment Response: February 5-6
- Consortium for Implementation Science (CCIS): February 26-28
- Announcing a New Toolkit to Support Health Systems Utilizing the National Standards for Cancer Survivorship Care
- 2023 Behavioral Risk Factor Surveillance System Dataset and Tools
- ASPO’s 2025 Annual Meeting Seeking Volunteer Co-Chairs
- Interdisciplinary Network for Survivorship and Primary Care Research: March 3
- Duke Cancer Institute Invited Scholar Research Symposium: March 20-21
- Precision Integrative Medicine for Cancer Survivors: January 14
- 13th Annual Symposium on Global Cancer Research: May 5-8
- DCB New Grantee Workshop: January 9-10
- Nature Webinar – The Human Tumor Atlas Network (HTAN): Exploring Tumor Evolution in Time and SpaceExit Disclaimer: January 14
- 2025 AACI Catchment Area Data Excellence (CADEx) Conference Acquisition, Analysis, Action: January 29-31
- 2025 AACI Leadership Diversity and Development Workshop: March 11-12
- 2025 AACI/AACR Hill Day: May 22
- 17th Annual AACI CRI Meeting: June 23-25
- 2025 AACI/CCAF Annual Meeting: October 19-21
- Frontiers Symposium on Transformation in Cancer Care Delivery: February 17-19
- The Human Tumor Atlas Network (HTAN): Exploring Tumor Evolution in Time and Space: January 14
- Consortium for Cancer Implementation Science (CCIS) Annual Meeting: February 26-28
Training Programs and Internships
- National Cancer Institutes’ (NCI) Intramural Continuing Umbrella Experiences (iCURE)
- 2025 Summer Undergraduate Research Fellowship (SURF) at Mayo Clinic
- T32 Postdoctoral Training in Behavioral Oncology
- Postdoctoral Positions Cancer Population Science Georgetown University Lombardi Comprehensive Cancer Center
- UIC Cancer Health Equity and Career Development Program for Pre/Post-Docs
- Fanconi Cancer Foundation- AACR NextGen Grant for Transformative Cancer Research
- Robert A Winn Diversity in Clinical Trials Award Program
- NCI Cancer Prevention Fellowship Program
- AACR-AstraZeneca Breast Cancer Research Fellowship for Endocrine Therapy Research
- OSUCCC Cancer Prevention and Cancer Control T32 postdoctoral Training Grant
- Postdoctoral Fellow – Centrosome, microscopy, cancer
- Postdoctoral Fellow – Redox Biology, DNA damage response
- 2025 Systems Approaches to Cancer Biology Scholars
More Trainee Resources
Email the Cancer Center’s Cancer Research Training and Education Coordination (CRTEC) team at [email protected].